Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 21 | 2020 | 62 | 4.240 |
Why?
|
| Muscle, Skeletal | 9 | 2019 | 494 | 1.250 |
Why?
|
| Charcot-Marie-Tooth Disease | 2 | 2019 | 6 | 1.050 |
Why?
|
| Ultrasonography | 9 | 2019 | 345 | 1.000 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2010 | 21 | 0.960 |
Why?
|
| Neural Conduction | 3 | 2020 | 81 | 0.930 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 9 | 0.760 |
Why?
|
| Mutation | 4 | 2019 | 466 | 0.700 |
Why?
|
| Hemifacial Spasm | 1 | 2019 | 3 | 0.700 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 72 | 0.690 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 77 | 0.690 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2018 | 1 | 0.680 |
Why?
|
| Trigeminal Neuralgia | 1 | 2019 | 33 | 0.680 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 6 | 0.680 |
Why?
|
| Family Health | 2 | 2017 | 78 | 0.680 |
Why?
|
| Nerve Tissue | 1 | 2018 | 2 | 0.680 |
Why?
|
| Immunologic Factors | 1 | 2018 | 48 | 0.650 |
Why?
|
| Humans | 41 | 2020 | 29093 | 0.650 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2017 | 2 | 0.610 |
Why?
|
| Gelsolin | 1 | 2017 | 2 | 0.610 |
Why?
|
| Amyloidosis, Familial | 1 | 2017 | 2 | 0.610 |
Why?
|
| Middle Aged | 26 | 2020 | 10829 | 0.600 |
Why?
|
| Muscles | 1 | 2017 | 53 | 0.600 |
Why?
|
| Electromyography | 3 | 2017 | 58 | 0.590 |
Why?
|
| Periventricular Nodular Heterotopia | 1 | 2016 | 1 | 0.580 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2016 | 5 | 0.570 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2016 | 3 | 0.570 |
Why?
|
| Peripheral Nerves | 2 | 2019 | 58 | 0.550 |
Why?
|
| Muscle Cramp | 1 | 2015 | 3 | 0.550 |
Why?
|
| Upper Extremity | 1 | 2016 | 52 | 0.550 |
Why?
|
| Male | 28 | 2020 | 17807 | 0.520 |
Why?
|
| Adult | 20 | 2020 | 8420 | 0.490 |
Why?
|
| Female | 28 | 2020 | 18164 | 0.480 |
Why?
|
| Brain | 1 | 2020 | 930 | 0.460 |
Why?
|
| Aged | 19 | 2020 | 9487 | 0.450 |
Why?
|
| Hematoma | 1 | 2011 | 23 | 0.410 |
Why?
|
| Neuromuscular Junction | 4 | 2018 | 67 | 0.410 |
Why?
|
| Myography | 3 | 2018 | 6 | 0.400 |
Why?
|
| Electric Impedance | 3 | 2018 | 13 | 0.400 |
Why?
|
| Stroke | 2 | 2009 | 545 | 0.390 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2010 | 1 | 0.390 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 2 | 0.390 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 4 | 0.390 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 50 | 0.380 |
Why?
|
| Cranial Nerves | 1 | 2009 | 7 | 0.360 |
Why?
|
| Thromboembolism | 1 | 2009 | 30 | 0.340 |
Why?
|
| Immunity | 2 | 2018 | 19 | 0.330 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 3717 | 0.320 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2006 | 1 | 0.280 |
Why?
|
| Sural Nerve | 2 | 2019 | 21 | 0.270 |
Why?
|
| Neuroprotective Agents | 2 | 2020 | 20 | 0.270 |
Why?
|
| Blepharoptosis | 1 | 2005 | 1 | 0.270 |
Why?
|
| Myasthenia Gravis | 1 | 2005 | 9 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 18 | 0.270 |
Why?
|
| Myelin P0 Protein | 2 | 2019 | 4 | 0.270 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 21 | 0.270 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 412 | 0.260 |
Why?
|
| Adolescent | 5 | 2020 | 3254 | 0.260 |
Why?
|
| Autoantibodies | 1 | 2005 | 41 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2019 | 859 | 0.250 |
Why?
|
| Median Nerve | 2 | 2017 | 44 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Ceftriaxone | 2 | 2014 | 11 | 0.240 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Research Design | 2 | 2016 | 286 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Cognition Disorders | 1 | 2006 | 390 | 0.220 |
Why?
|
| Young Adult | 5 | 2020 | 2402 | 0.210 |
Why?
|
| Evoked Potentials, Motor | 2 | 2018 | 8 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 285 | 0.200 |
Why?
|
| Time Factors | 3 | 2020 | 2001 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2019 | 6 | 0.170 |
Why?
|
| Myositis, Inclusion Body | 1 | 2019 | 7 | 0.170 |
Why?
|
| Pedigree | 1 | 2019 | 133 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2019 | 28 | 0.170 |
Why?
|
| Sample Size | 1 | 2018 | 37 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2018 | 30 | 0.170 |
Why?
|
| Family | 1 | 2019 | 105 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 96 | 0.160 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 47 | 0.160 |
Why?
|
| Psychometrics | 1 | 2018 | 129 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1356 | 0.150 |
Why?
|
| Disease Progression | 5 | 2020 | 572 | 0.150 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 629 | 0.150 |
Why?
|
| Extremities | 1 | 2017 | 48 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 67 | 0.150 |
Why?
|
| Scapula | 1 | 2017 | 18 | 0.150 |
Why?
|
| Wrist | 1 | 2017 | 39 | 0.150 |
Why?
|
| Neuromuscular Agents | 1 | 2017 | 28 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 37 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 298 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 720 | 0.140 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 24 | 0.140 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2016 | 3 | 0.140 |
Why?
|
| Huntington Disease | 1 | 2016 | 14 | 0.140 |
Why?
|
| Ulnar Neuropathies | 1 | 2015 | 16 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 148 | 0.130 |
Why?
|
| Inflammation | 1 | 2018 | 507 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2015 | 61 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1218 | 0.130 |
Why?
|
| Myelin Proteins | 1 | 2014 | 3 | 0.130 |
Why?
|
| Vital Capacity | 3 | 2018 | 44 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 493 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 464 | 0.120 |
Why?
|
| Plant Oils | 1 | 2013 | 14 | 0.110 |
Why?
|
| Motor Neurons | 2 | 2010 | 53 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 816 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 196 | 0.110 |
Why?
|
| Age of Onset | 2 | 2016 | 95 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2013 | 170 | 0.100 |
Why?
|
| African Americans | 1 | 2019 | 1373 | 0.100 |
Why?
|
| Muscular Atrophy | 1 | 2011 | 67 | 0.100 |
Why?
|
| Motor Neuron Disease | 1 | 2010 | 4 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2010 | 12 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 726 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2020 | 501 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2009 | 140 | 0.080 |
Why?
|
| Apoptosis | 1 | 2010 | 337 | 0.080 |
Why?
|
| Peripheral Nervous System | 1 | 2008 | 6 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3111 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 51 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2009 | 447 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 25 | 0.080 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 11 | 0.070 |
Why?
|
| Electrodiagnosis | 2 | 2017 | 35 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2006 | 19 | 0.070 |
Why?
|
| Animals | 5 | 2018 | 7297 | 0.070 |
Why?
|
| Epilepsy | 1 | 2006 | 59 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 980 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 795 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2018 | 1687 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 2019 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1013 | 0.050 |
Why?
|
| Risk Factors | 1 | 2009 | 3531 | 0.050 |
Why?
|
| Time | 1 | 2020 | 21 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2108 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 23 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 641 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3099 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2020 | 86 | 0.050 |
Why?
|
| Forearm | 1 | 2019 | 33 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Diaphragm | 1 | 2018 | 46 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 454 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 532 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 14 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2017 | 28 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 469 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 863 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2017 | 39 | 0.040 |
Why?
|
| Head | 1 | 2017 | 47 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2016 | 165 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 22 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 55 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 85 | 0.030 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 4 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 104 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 519 | 0.030 |
Why?
|
| Semaphorins | 1 | 2010 | 2 | 0.020 |
Why?
|
| Growth Cones | 1 | 2010 | 3 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 11 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 10 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 20 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 27 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 73 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 129 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 106 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 192 | 0.020 |
Why?
|
| Ganglia, Spinal | 1 | 2010 | 63 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 92 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 272 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 799 | 0.020 |
Why?
|
| Riluzole | 1 | 2007 | 5 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 224 | 0.020 |
Why?
|
| Hindlimb | 1 | 2007 | 57 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 249 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2007 | 139 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 264 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 310 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 1108 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 2368 | 0.010 |
Why?
|